USE1
Vesicle transport protein USE1
Also known as: D12, MDS032, p31, SLT1, USE1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9NZ43
- Gene
- USE1
- Ensembl
- ENSG00000053501
- Chromosome
- 19
- Canonical length
- 259 aa
- Protein class
- Predicted intracellular proteins, Predicted membrane proteins
OverviewNCBI Gene
Predicted to enable SNAP receptor activity. Predicted to be involved in several processes, including lysosomal transport; protein catabolic process; and retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum. Predicted to act upstream of or within endoplasmic reticulum tubular network organization and regulation of ER to Golgi vesicle-mediated transport. Located in endoplasmic reticulum. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
259 residues, UniProt reviewed canonical sequence.
>Q9NZ43|USE1
1 MAASRLELNL VRLLSRCEAM AAEKRDPDEW RLEKYVGALE DMLQALKVHA SKPASEVINE
61 YSWKVDFLKG MLQAEKLTSS SEKALANQFL APGRVPTTAR ERVPATKTVH LQSRARYTSE
121 MRSELLGTDS AEPEMDVRKR TGVAGSQPVS EKQLAAELDL VLQRHQNLQE KLAEEMLGLA
181 RSLKTNTLAA QSVIKKDNQT LSHSLKMADQ NLEKLKTESE RLEQHTQKSV NWLLWAMLII
241 VCFIFISMIL FIRIMPKLKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against USE1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.46
- Highest tissue expression
- 57 nTPM
Expression across tissuesHPA
Tissue
- amygdala: 57 nTPM
- skeletal muscle: 54 nTPM
- cerebral cortex: 54 nTPM
- hippocampal formation: 50 nTPM
- midbrain: 46 nTPM
- heart muscle: 44 nTPM
Single-cell type
- late spermatids: 226 nCPM
- syncytiotrophoblasts: 93 nCPM
- esophageal basal cells: 87 nCPM
- esophageal apical cells: 81 nCPM
- decidual stromal cells: 80 nCPM
- esophageal suprabasal cells: 79 nCPM
Immune cell
- memory B-cell: 140 nTPM
- naive B-cell: 129 nTPM
- naive CD4 T-cell: 116 nTPM
- plasmacytoid DC: 87 nTPM
- naive CD8 T-cell: 87 nTPM
- T-reg: 85 nTPM
Brain region
- white matter: 39 nTPM
- medulla oblongata: 33 nTPM
- basal ganglia: 33 nTPM
- midbrain: 32 nTPM
- pons: 32 nTPM
- hypothalamus: 31 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.99
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.52
- DepMap mean gene effect
- -0.44
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- endoplasmic reticulum tubular network organization
- lysosomal transport
- protein catabolic process
- protein transport
- regulation of ER to Golgi vesicle-mediated transport
- retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum
- secretion by cell
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Vesicle transport protein, Use1
- Membrane fusion protein Use1
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of USE1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads USE1 as an antibody target. Whether an autoantibody or antibody against USE1 could matter depends on whether native USE1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
USE1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label USE1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...